Archive for August, 2011

Using HIV-Infected Organs for Transplants

August 27th, 2011

The world’s first organ transplants from an HIV-positive donor to HIV-positive recipients took place in Cape Town, South Africa in 2008. Two kidney transplants were carried out at Cape Town’s Groote Schuur hospital in September that year and the surgeons who carried out the operations reported that the operations were quite successful and both recipients of the kidneys were doing well. Before then, the organs of HIV-positive patients were simply discarded and until recently, HIV-positive patients were also not eligible for organ transplants. This is because most experts believed that the organs should go to people with a better chance of survival. However, in the late 1990s, owing to the introduction of potent antiretroviral therapy, survival rate for people living with HIV increased substantially, putting an end to the arguments that they were less likely to live than their HIV-negative counterparts.

In the United States however, there is still an over a decade-old ban on using organs from HIV-positive donors. This ban was put in place in the 1980s around the same time bans were put in place prohibiting people with HIV from donating blood. As at that period, people with HIV were also excluded as viable candidates for receiving organ transplants, which has now been lifted. But the primary challenge now is the availability of viable organs for transplant. This means that many people – both HIV-positive and HIV-negative – die waiting for an organ from a matched donor. A new Johns Hopkins research suggests that if the U.S. Congress reversed its ban on allowing people with HIV to be organ donors after their death, about 500 HIV-positive patients with kidney or liver failure each year could get transplants within months, rather than the years they currently wait on the list.

The study’s senior author Dorry L. Segev, an associate professor of surgery at the Johns Hopkins University School of Medicine said that every single HIV-infected transplant candidate would get organ for transplant if this ban is lifted. “Instead of discarding the otherwise healthy organs of HIV-infected people when they die, those organs could be available for HIV-positive candidates”, he says. Not only would HIV-positive transplant candidates get organs sooner if such transplants were legalized, but by transplanting those patients and moving them off the waiting list, the time to transplant would be shorter for non-HIV-infected patients. Segev reports that the number of HIV-positive patients receiving kidney or liver transplants – with non-HIV infected organs – is on the rise as doctors become more comfortable with the idea, and patients are having good outcomes. The online science news website, ScienceDaily reports that in 2009, more than 100 HIV-positive patients got new kidneys and 29 got new livers. There have been various reports on the toxic effects of anti-retroviral drugs on the liver and kidney. These drugs are used to control HIV-infection in the body but consequently have toxic effects on the liver and kidneys. This and some other factors may lead to complete organ failure. As a result, HIV-infected patients may encounter accelerated rates of liver and kidney disease.

Segev and his colleagues set out in their study, published online in the American Journal of Transplantation, to estimate the number of people who die each year in the United States who are good potential organ donors except for that they are HIV-positive. They culled data from two main sources – the Nationwide Inpatient Study, and the HIV Research Network. The team discovered that the number of annual deaths with what are believed to be organs viable for transplant to be approximately the same – about 500.

There may be risks associated with allowing HIV-positive individuals donate organs for transplant. Some medical and safety issues need to be addressed. Doctors need to ensure that the donor organs are healthy enough for transplant. If the donor organ has been damaged by the illness, this significantly lowers the life span of the organ. There is also the fear hat recipient may be infected with a more virulent strain of the virus in this process. Mislabeling an HIV-infected organ and transplanting it to an HIV-negative person is also another issue to be considered. However, considering the potential benefits of using HIV-infected organs for transplant, these challenges are overshadowed. Patients will have to consider the prospect of a life on dialysis (for those with a damaged kidney), or premature death while waiting for a transplant, and eventually opt to take the risk.

New Findings Towards HIV Eradication

August 20th, 2011

People who have been following the story of patients who currently have HIV know that one of the big problems has been the amount of money that treatment drugs actually cost. The good news is that HIV is treatable, and those with the funding can get drugs that allow them to live as if they had never contracted this terrible illness. If you are wondering how much HIV medication costs, however, you might be surprised to find that it can cost over 600,000 dollars. This means that unless you have a great financial support line or insurance, you are going to have trouble keeping up with these medical payments.

There is even better news, however. A company may have just found a solution that can actually help people who have HIV to never take medication again. Your first response might be that this sounds like the impossible: a way to exile this virus from the body. This isn’t quite true, though it can indeed cure people who have HIV of this virus. Instead of killing the virus in a way that you might imagine, the drug called KP-1461 actually causes HIV to mutate. In a sense, it causes the virus to self destruct. This is a brilliant finding, though it’s not all over yet. There still is more work to do.

What is the problem? Why don’t they just go ahead and find a cure for HIV? Unfortunately, the medication and HIV treatment industry is big business. This is a 14 billion dollar a year industry. If you are wondering who is making big money from this medication, you can take a close look at the drug companies. Regardless of what you think about this truth, you should understand that these companies don’t have a lot of interest in helping developing KP-1461 since it would pretty much enable thousands of HIV patients to save money and to live a life without drugs. It could be a miracle for some and death sentence for others.

If you are wondering how to take this information, it depends largely on if you are an optimist or a pessimist. On the one hand, you can be hopeful that this medication revolution is at least being considered. On the other hand, it’s important that you understand this medication is not yet perfected. Even if it is successful in development, this is a slow acting drug that takes years to be fully effective and it may not be effective on all HIV patients.